Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system

Gene Therapy

Volumn 5, Issue 4, 1998, Pages 531-536

  Hofmann, C ^a   Strauss, M ^b,c  

^a HepaVec AG für Gentherapie   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Baculovirus vectors; Complement inhibitors; Complement system; Hepatocytes; Liver gene therapy

Indexed keywords

COBROTOXIN; COMPLEMENT; VIRUS VECTOR;

ARTICLE; BACULOVIRUS; BLOOD; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; GENE TRANSFER; HUMAN; LIVER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SERUM;

UNIDENTIFIED BACULOVIRUS;

EID: 0031942299     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300607     Document Type: Article

References (44)

1. Sandig V, Strauss M. Liver-directed gene transfer and application to therapy. J Mol Med 1996; 74: 205-212.
2. Hofmann C et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92: 10099-11103.
3. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA 1996; 93: 2348-2352.
4. Sandig V et al. Gene transfer into hepatocytes and human liver tissue by baculovirus vectors. Hum Gene Ther 1996; 7: 1937-1945.
5. Liszewski K, Atkinson JP. The complement system. In: William PE (ed). Fundamental Immunology. Raven Press: New York, 1993, pp 917-939.
6. Tomlinson S. Complement defense mechanisms. Curr Opin Immunol 1993; 5: 83-89.
7. Szeberd J et al. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Commun 1994; 205: 255-263.
8. Marjan J, Xie Z, Devine DV. Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim Biophys Acta 1994; 1192: 35-44.
9. Szebeni J, Wassef NM, Rudolph AS, Alving CR. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys Acta 1996; 1285: 127-130.
10. Plank C, Mechtler K, Szoka FC Jr, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996, 7: 1437-1446.
11. Welsh RM Jr, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumour viruses. Nature 1975; 257: 612-614.
12. Bartholomew RM, Esser AF. Mechanism of antibody-independent activation of the first component of complement (Cl) on retrovirus membranes. Biochemistry 1980; 19: 2847-2853.
13. Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
14. Matsushita M. The lectin pathway of the complement system. Microbiol Immunol 1996; 40: 887-893.
15. Fritzinger DC, Bredehorst R, Vogel CW. Molecular cloning and derived primary structure of cobra venom factor (published erratum appears in Proc Natl Acad Sci USA 1995; 92: 7605. Proc Natl Acad Sci USA 1994; 91: 12775-12779.
16. Cochrane CG, Müller-Eberhard HJ. Depletion of plasma complement in vivo by a protein of cobra venom: its effect of various immunologic reactions. J Immunol 1970; 105: 55-69.
17. O'Reilly OR, Miller LK, Luckow VA. Virus host interactions. In: Baculovirus Expression Vectors: A Laboratory Manual. Oxford University Press, New York, Oxford, 1994, pp 29.
18. Crossen R, Gruenwald S. Baculovirus Expression Vector System Manual. PharMingen: San Diego, CA, 1996.
19. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11: 402-406.
20. Harashima H et al. Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharm Res 1996; 13: 1704-1709.
21. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146: 4234-4241.
22. Takeuchi Y et al. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase. Nature 1996; 379: 85-88.
23. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995; 6: 429-435.
24. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serin protease. J Exp Med 1992; 176: 1497-1502.
25. Thiel S et al. A second serine protease associated with mannan-bindmg lectin that activates complement. Nature 1997; 386: 506-510.
26. Podack ER, Müller-Eberhardt HJ. Binding of deoxycholate, phosphatidyl choline vesicles, lipoprotein or S-protein to complexes of terminal complement components. J Immunol 1978; 121: 1025-1030.
27. Silversmith RE, Nelsestuen GL. Interaction of complement proteins C5b-6 and C5b-7 with phospholipid vesicles: effects of phospholipid structural features. Biochemistry 1986; 25: 7717-7725.
28. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-8007.
29. Kroshus TJ et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig to human xenotransplantation. Transplantation 1995; 60: 1194-1202.
30. Evans MJ et al. In vitro and in vivo inhibition of complement activity by a single chain FV fragment recognizing human C5. Mol Immunol 1995; 32: 1183-1195.
31. Lynch DM, Kay PH. Studies on the polymorphism of the fifth component of complement in laboratory mice. Exp Clin Immunogenet 1995; 12: 253-260.
32. Trinder PK et al. Functional domains of the human C1qA-chain. Behring Inst Mitt 1993; 93: 180-188.
33. Sahu A, Pangburn MK. Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993; 30: 679-684.
34. Hirsch LH, Griffin DE, Winkelstein JA. Host modification of sindbis virus sialic acid content influences alternative complement pathway activation and virus clearence J Immunol 1981; 127: 1740-1743.
35. Leventhal JR et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-865.
36. Liu D, Hu Q, Song YK. Liposomal clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1995; 1240: 277-284.
37. Azimzadeh A et al. Assessment of hyperacute rejection in a rat-to-primate cardiac xenograft model. Transplantation 1996, 61: 1305-1313.
38. Weisman HF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-151.
39. Ferry N et al. Retroviral-mediated gene transfer into hepatocytes in viva. Proc Natl Acad Sci USA 1991; 88: 8377-8381.
40. Cardoso JE et al. In situ retrovirus-mediated gene transfer into dog liver. Hum Gene Ther 1993; 4: 411-418.
41. Rettinger SD et al. In vivo hepatocyte transduction with retrovirus during in-flow occlusion. J Surg Res 1993; 54: 418-425.
42. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Ann Rev Immunol 1989; 7: 35-38.
43. Nakabayashi H et al. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863.
44. Mimms LT et al. Discrimination of hepatitis B virus (HBV) subtypes using monoclonal antibodies to the PreS1 and PreS2 domains of the viral envelope. Virology 1990; 176: 604-619.